APO Research
Talk to an analyst

APO RESEARCH · REPORT

GalNAc-based Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global GalNAc-based Drug Market Analysis and Forecast 2026-2032

29 December 2025192 pages

Choose your research edition.

Industry ResearchGalNAc-based Drug Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal GalNAc-based Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal GalNAc-based Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GalNAc-based Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal GalNAc-based Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global GalNAc-based Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for GalNAc-based Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for GalNAc-based Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for GalNAc-based Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for GalNAc-based Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of GalNAc-based Drug include Suzhou Ribo Life Science Co., Ltd, Sirnaomics, Novartis, Novo Nordisk (Dicerna), Hitgen (Leaderna Therapeutics Ltd.), Silence Therapeutics, Ionis, Arrowhead and Arbutus, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for GalNAc-based Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of GalNAc-based Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for GalNAc-based Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the GalNAc-based Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global GalNAc-based Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for GalNAc-based Drug revenue, projected growth trends, production technology, application and end-user industry.

GalNAc-based Drug Segment by Company

Suzhou Ribo Life Science Co., Ltd

Sirnaomics

Novartis

Novo Nordisk (Dicerna)

Hitgen (Leaderna Therapeutics Ltd.)

Silence Therapeutics

Ionis

Arrowhead

Arbutus

Alnylam Pharmaceuticals

GalNAc-based Drug Segment by Type

siRNA Based

ASO Based

GalNAc-based Drug Segment by Application

Metabolic Diseases

Neurological Diseases

Cardiovascular Diseases

Other

GalNAc-based Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GalNAc-based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GalNAc-based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GalNAc-based Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of GalNAc-based Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of GalNAc-based Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, GalNAc-based Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global GalNAc-based Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. siRNA Based Major Player Table 3. ASO Based Major Player Table 4. Global GalNAc-based Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Metabolic Diseases Major Player Table 6. Neurological Diseases Major Player Table 7. Cardiovascular Diseases Major Player Table 8. Other Major Player Table 9. GalNAc-based Drug Industry Trends Table 10. GalNAc-based Drug Industry Drivers Table 11. GalNAc-based Drug Industry Opportunities and Challenges Table 12. GalNAc-based Drug Industry Restraints Table 13. Global GalNAc-based Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global GalNAc-based Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global GalNAc-based Drug Market Share by Region (2021-2026) Table 16. Global GalNAc-based Drug Market Size by Region (2027-2032) & (US$ Million) Table 17. Global GalNAc-based Drug Market Share by Region (2027-2032) Table 18. Global GalNAc-based Drug Revenue by Players (US$ Million) & (2021-2026) Table 19. Global GalNAc-based Drug Revenue Market Share by Players (2021-2026) Table 20. Global GalNAc-based Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global GalNAc-based Drug Key Players Headquarters & Area Served Table 22. Global GalNAc-based Drug Players, Product Type & Application Table 23. Global GalNAc-based Drug Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global GalNAc-based Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global GalNAc-based Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global GalNAc-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 28. Global GalNAc-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 29. Global GalNAc-based Drug Revenue Market Share by Type (2021-2026) Table 30. Global GalNAc-based Drug Revenue Market Share by Type (2027-2032) Table 31. Global GalNAc-based Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global GalNAc-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 33. Global GalNAc-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 34. Global GalNAc-based Drug Revenue Market Share by Application (2021-2026) Table 35. Global GalNAc-based Drug Revenue Market Share by Application (2027-2032) Table 36. Suzhou Ribo Life Science Co., Ltd Company Information Table 37. Suzhou Ribo Life Science Co., Ltd Business Overview Table 38. Suzhou Ribo Life Science Co., Ltd GalNAc-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Suzhou Ribo Life Science Co., Ltd GalNAc-based Drug Product Portfolio Table 40. Suzhou Ribo Life Science Co., Ltd Recent Development Table 41. Sirnaomics Company Information Table 42. Sirnaomics Business Overview Table 43. Sirnaomics GalNAc-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Sirnaomics GalNAc-based Drug Product Portfolio Table 45. Sirnaomics Recent Development Table 46. Novartis Company Information Table 47. Novartis Business Overview Table 48. Novartis GalNAc-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Novartis GalNAc-based Drug Product Portfolio Table 50. Novartis Recent Development Table 51. Novo Nordisk (Dicerna) Company Information Table 52. Novo Nordisk (Dicerna) Business Overview Table 53. Novo Nordisk (Dicerna) GalNAc-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Novo Nordisk (Dicerna) GalNAc-based Drug Product Portfolio Table 55. Novo Nordisk (Dicerna) Recent Development Table 56. Hitgen (Leaderna Therapeutics Ltd.) Company Information Table 57. Hitgen (Leaderna Therapeutics Ltd.) Business Overview Table 58. Hitgen (Leaderna Therapeutics Ltd.) GalNAc-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Hitgen (Leaderna Therapeutics Ltd.) GalNAc-based Drug Product Portfolio Table 60. Hitgen (Leaderna Therapeutics Ltd.) Recent Development Table 61. Silence Therapeutics Company Information Table 62. Silence Therapeutics Business Overview Table 63. Silence Therapeutics GalNAc-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Silence Therapeutics GalNAc-based Drug Product Portfolio Table 65. Silence Therapeutics Recent Development Table 66. Ionis Company Information Table 67. Ionis Business Overview Table 68. Ionis GalNAc-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Ionis GalNAc-based Drug Product Portfolio Table 70. Ionis Recent Development Table 71. Arrowhead Company Information Table 72. Arrowhead Business Overview Table 73. Arrowhead GalNAc-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Arrowhead GalNAc-based Drug Product Portfolio Table 75. Arrowhead Recent Development Table 76. Arbutus Company Information Table 77. Arbutus Business Overview Table 78. Arbutus GalNAc-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Arbutus GalNAc-based Drug Product Portfolio Table 80. Arbutus Recent Development Table 81. Alnylam Pharmaceuticals Company Information Table 82. Alnylam Pharmaceuticals Business Overview Table 83. Alnylam Pharmaceuticals GalNAc-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Alnylam Pharmaceuticals GalNAc-based Drug Product Portfolio Table 85. Alnylam Pharmaceuticals Recent Development Table 86. North America GalNAc-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 87. North America GalNAc-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 88. North America GalNAc-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 89. North America GalNAc-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 90. North America GalNAc-based Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. North America GalNAc-based Drug Revenue by Country (2021-2026) & (US$ Million) Table 92. North America GalNAc-based Drug Revenue by Country (US$ Million) & (2027-2032) Table 93. Europe GalNAc-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 94. Europe GalNAc-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 95. Europe GalNAc-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 96. Europe GalNAc-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 97. Europe GalNAc-based Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. Europe GalNAc-based Drug Revenue by Country (2021-2026) & (US$ Million) Table 99. Europe GalNAc-based Drug Revenue by Country (US$ Million) & (2027-2032) Table 100. China GalNAc-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 101. China GalNAc-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 102. China GalNAc-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 103. China GalNAc-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 104. Asia GalNAc-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 105. Asia GalNAc-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 106. Asia GalNAc-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 107. Asia GalNAc-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 108. Asia GalNAc-based Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 109. Asia GalNAc-based Drug Revenue by Region (US$ Million) & (2021-2026) Table 110. Asia GalNAc-based Drug Revenue by Region (US$ Million) & (2027-2032) Table 111. SAMEA GalNAc-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 112. SAMEA GalNAc-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 113. SAMEA GalNAc-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 114. SAMEA GalNAc-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 115. SAMEA GalNAc-based Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. SAMEA GalNAc-based Drug Revenue by Country (2021-2026) & (US$ Million) Table 117. SAMEA GalNAc-based Drug Revenue by Country (US$ Million) & (2027-2032) Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. GalNAc-based Drug Image Figure 2. Global GalNAc-based Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GalNAc-based Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. siRNA Based Image Figure 5. ASO Based Image Figure 6. Global GalNAc-based Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global GalNAc-based Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. Metabolic Diseases Image Figure 9. Neurological Diseases Image Figure 10. Cardiovascular Diseases Image Figure 11. Other Image Figure 12. Global GalNAc-based Drug Market Size (US$ Million) & (2021-2032) Figure 13. Global GalNAc-based Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global GalNAc-based Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global GalNAc-based Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global GalNAc-based Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global GalNAc-based Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global GalNAc-based Drug Revenue Market Share by Type (2021-2032) Figure 20. Global GalNAc-based Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global GalNAc-based Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global GalNAc-based Drug Revenue Market Share by Application (2021-2032) Figure 23. North America GalNAc-based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America GalNAc-based Drug Revenue Share by Type (2021-2032) Figure 25. North America GalNAc-based Drug Revenue Share by Application (2021-2032) Figure 26. North America GalNAc-based Drug Revenue Share by Country (2021-2032) Figure 27. United States GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe GalNAc-based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe GalNAc-based Drug Revenue Share by Type (2021-2032) Figure 32. Europe GalNAc-based Drug Revenue Share by Application (2021-2032) Figure 33. Europe GalNAc-based Drug Revenue Share by Country (2021-2032) Figure 34. Germany GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China GalNAc-based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China GalNAc-based Drug Revenue Share by Type (2021-2032) Figure 44. China GalNAc-based Drug Revenue Share by Application (2021-2032) Figure 45. Asia GalNAc-based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia GalNAc-based Drug Revenue Share by Type (2021-2032) Figure 47. Asia GalNAc-based Drug Revenue Share by Application (2021-2032) Figure 48. Asia GalNAc-based Drug Revenue Share by Region (2021-2032) Figure 49. Japan GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA GalNAc-based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA GalNAc-based Drug Revenue Share by Type (2021-2032) Figure 57. SAMEA GalNAc-based Drug Revenue Share by Application (2021-2032) Figure 58. SAMEA GalNAc-based Drug Revenue Share by Country (2021-2032) Figure 59. Brazil GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt GalNAc-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • siRNA Based
  • ASO Based
Applications
  • Metabolic Diseases
  • Neurological Diseases
  • Cardiovascular Diseases
  • Other
Companies covered
  • Suzhou Ribo Life Science Co., Ltd
  • Sirnaomics
  • Novartis
  • Novo Nordisk (Dicerna)
  • Hitgen (Leaderna Therapeutics Ltd.)
  • Silence Therapeutics
  • Ionis
  • Arrowhead
  • Arbutus
  • Alnylam Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 GalNAc-based Drug Market by Type
  3. 1.2.1 Global GalNAc-based Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 siRNA Based
  5. 1.2.3 ASO Based
  6. 1.3 GalNAc-based Drug Market by Application
  7. 1.3.1 Global GalNAc-based Drug Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Metabolic Diseases
  9. 1.3.3 Neurological Diseases
  10. 1.3.4 Cardiovascular Diseases
  11. 1.3.5 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 GalNAc-based Drug Market Dynamics
  1. 2.1 GalNAc-based Drug Industry Trends
  2. 2.2 GalNAc-based Drug Industry Drivers
  3. 2.3 GalNAc-based Drug Industry Opportunities and Challenges
  4. 2.4 GalNAc-based Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global GalNAc-based Drug Market Perspective (2021-2032)
  2. 3.2 Global GalNAc-based Drug Growth Trends by Region
  3. 3.2.1 Global GalNAc-based Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global GalNAc-based Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global GalNAc-based Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global GalNAc-based Drug Revenue by Players
  2. 4.1.1 Global GalNAc-based Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global GalNAc-based Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global GalNAc-based Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global GalNAc-based Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global GalNAc-based Drug Key Players Headquarters & Area Served
  7. 4.4 Global GalNAc-based Drug Players, Product Type & Application
  8. 4.5 Global GalNAc-based Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global GalNAc-based Drug Market CR5 and HHI
  11. 4.6.3 2025 GalNAc-based Drug Tier 1, Tier 2, and Tier 3
5 GalNAc-based Drug Market Size by Type
  1. 5.1 Global GalNAc-based Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global GalNAc-based Drug Revenue by Type (2021-2032)
  3. 5.3 Global GalNAc-based Drug Revenue Market Share by Type (2021-2032)
6 GalNAc-based Drug Market Size by Application
  1. 6.1 Global GalNAc-based Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global GalNAc-based Drug Revenue by Application (2021-2032)
  3. 6.3 Global GalNAc-based Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Suzhou Ribo Life Science Co., Ltd
  2. 7.1.1 Suzhou Ribo Life Science Co., Ltd Company Information
  3. 7.1.2 Suzhou Ribo Life Science Co., Ltd Business Overview
  4. 7.1.3 Suzhou Ribo Life Science Co., Ltd GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Suzhou Ribo Life Science Co., Ltd GalNAc-based Drug Product Portfolio
  6. 7.1.5 Suzhou Ribo Life Science Co., Ltd Recent Developments
  7. 7.2 Sirnaomics
  8. 7.2.1 Sirnaomics Company Information
  9. 7.2.2 Sirnaomics Business Overview
  10. 7.2.3 Sirnaomics GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sirnaomics GalNAc-based Drug Product Portfolio
  12. 7.2.5 Sirnaomics Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis GalNAc-based Drug Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Novo Nordisk (Dicerna)
  20. 7.4.1 Novo Nordisk (Dicerna) Company Information
  21. 7.4.2 Novo Nordisk (Dicerna) Business Overview
  22. 7.4.3 Novo Nordisk (Dicerna) GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novo Nordisk (Dicerna) GalNAc-based Drug Product Portfolio
  24. 7.4.5 Novo Nordisk (Dicerna) Recent Developments
  25. 7.5 Hitgen (Leaderna Therapeutics Ltd.)
  26. 7.5.1 Hitgen (Leaderna Therapeutics Ltd.) Company Information
  27. 7.5.2 Hitgen (Leaderna Therapeutics Ltd.) Business Overview
  28. 7.5.3 Hitgen (Leaderna Therapeutics Ltd.) GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Hitgen (Leaderna Therapeutics Ltd.) GalNAc-based Drug Product Portfolio
  30. 7.5.5 Hitgen (Leaderna Therapeutics Ltd.) Recent Developments
  31. 7.6 Silence Therapeutics
  32. 7.6.1 Silence Therapeutics Company Information
  33. 7.6.2 Silence Therapeutics Business Overview
  34. 7.6.3 Silence Therapeutics GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Silence Therapeutics GalNAc-based Drug Product Portfolio
  36. 7.6.5 Silence Therapeutics Recent Developments
  37. 7.7 Ionis
  38. 7.7.1 Ionis Company Information
  39. 7.7.2 Ionis Business Overview
  40. 7.7.3 Ionis GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Ionis GalNAc-based Drug Product Portfolio
  42. 7.7.5 Ionis Recent Developments
  43. 7.8 Arrowhead
  44. 7.8.1 Arrowhead Company Information
  45. 7.8.2 Arrowhead Business Overview
  46. 7.8.3 Arrowhead GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Arrowhead GalNAc-based Drug Product Portfolio
  48. 7.8.5 Arrowhead Recent Developments
  49. 7.9 Arbutus
  50. 7.9.1 Arbutus Company Information
  51. 7.9.2 Arbutus Business Overview
  52. 7.9.3 Arbutus GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Arbutus GalNAc-based Drug Product Portfolio
  54. 7.9.5 Arbutus Recent Developments
  55. 7.10 Alnylam Pharmaceuticals
  56. 7.10.1 Alnylam Pharmaceuticals Company Information
  57. 7.10.2 Alnylam Pharmaceuticals Business Overview
  58. 7.10.3 Alnylam Pharmaceuticals GalNAc-based Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Alnylam Pharmaceuticals GalNAc-based Drug Product Portfolio
  60. 7.10.5 Alnylam Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America GalNAc-based Drug Revenue (2021-2032)
  2. 8.2 North America GalNAc-based Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America GalNAc-based Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America GalNAc-based Drug Revenue by Type (2027-2032)
  5. 8.3 North America GalNAc-based Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America GalNAc-based Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America GalNAc-based Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America GalNAc-based Drug Revenue by Application (2027-2032)
  9. 8.5 North America GalNAc-based Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America GalNAc-based Drug Revenue by Country
  11. 8.6.1 North America GalNAc-based Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America GalNAc-based Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America GalNAc-based Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe GalNAc-based Drug Revenue (2021-2032)
  2. 9.2 Europe GalNAc-based Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe GalNAc-based Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe GalNAc-based Drug Revenue by Type (2027-2032)
  5. 9.3 Europe GalNAc-based Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe GalNAc-based Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe GalNAc-based Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe GalNAc-based Drug Revenue by Application (2027-2032)
  9. 9.5 Europe GalNAc-based Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe GalNAc-based Drug Revenue by Country
  11. 9.6.1 Europe GalNAc-based Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe GalNAc-based Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe GalNAc-based Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China GalNAc-based Drug Revenue (2021-2032)
  2. 10.2 China GalNAc-based Drug Revenue by Type (2021-2032)
  3. 10.2.1 China GalNAc-based Drug Revenue by Type (2021-2026)
  4. 10.2.2 China GalNAc-based Drug Revenue by Type (2027-2032)
  5. 10.3 China GalNAc-based Drug Revenue Share by Type (2021-2032)
  6. 10.4 China GalNAc-based Drug Revenue by Application (2021-2032)
  7. 10.4.1 China GalNAc-based Drug Revenue by Application (2021-2026)
  8. 10.4.2 China GalNAc-based Drug Revenue by Application (2027-2032)
  9. 10.5 China GalNAc-based Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia GalNAc-based Drug Revenue (2021-2032)
  2. 11.2 Asia GalNAc-based Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia GalNAc-based Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia GalNAc-based Drug Revenue by Type (2027-2032)
  5. 11.3 Asia GalNAc-based Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia GalNAc-based Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia GalNAc-based Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia GalNAc-based Drug Revenue by Application (2027-2032)
  9. 11.5 Asia GalNAc-based Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia GalNAc-based Drug Revenue by Country
  11. 11.6.1 Asia GalNAc-based Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia GalNAc-based Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia GalNAc-based Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA GalNAc-based Drug Revenue (2021-2032)
  2. 12.2 SAMEA GalNAc-based Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA GalNAc-based Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA GalNAc-based Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA GalNAc-based Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA GalNAc-based Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA GalNAc-based Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA GalNAc-based Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA GalNAc-based Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA GalNAc-based Drug Revenue by Country
  11. 12.6.1 SAMEA GalNAc-based Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA GalNAc-based Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA GalNAc-based Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst